Strongyloidiasis screening: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:


==Screening==
==Screening==
According to the CDC, screening for strongyloidiasis is not recommended.
*Most fatal infections caused by S.stercoralis can be prevented by early detection and treatment of asymptomatic chronic infections.<ref name="pmid22691685">{{cite journal |vauthors=Mejia R, Nutman TB |title=Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis |journal=Curr. Opin. Infect. Dis. |volume=25 |issue=4 |pages=458–63 |year=2012 |pmid=22691685 |pmc=3430846 |doi= |url=}}</ref><ref name="pmid19700900">{{cite journal |vauthors=Al Maslamani MA, Al Soub HA, Al Khal AL, Al Bozom IA, Abu Khattab MJ, Chacko KC |title=Strongyloides stercoralis hyperinfection after corticosteroid therapy: a report of two cases |journal=Ann Saudi Med |volume=29 |issue=5 |pages=397–401 |year=2009 |pmid=19700900 |pmc=2860402 |doi= |url=}}</ref>
*Screening is highly recommended to detect latent S.stercoralis infection before the start of chemotherapy or immunosuppression/steroid therapy in patients at risk.<ref name="urlDepartment of Health | Prevention of opportunistic infections in immunosuppressed patients in the tropical Top End of the Northern Territory of Australia">{{cite web |url=http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-cdi-2003-cdi2704-htm-cdi2704s.htm |title=Department of Health &#124; Prevention of opportunistic infections in immunosuppressed patients in the tropical Top End of the Northern Territory of Australia |format= |work= |accessdate=}}</ref>
*Repeated stool examination for ova and parasites or agar culture of stool may be the most appropriate approach.
==Population at risk==
*In the U.S., residents of the Southeast may be at risk for strongyloidiasis by growing up in an endemic area.
*Travelers and armed forces personnel may acquire infection during overseas trips to endemic areas (eg, southeast Asia, Central and South America, and Africa).
*Refugees and immigrants from endemic areas
*Immunocompromised patients, especially on corticosteroid therapy, are the most vulnerable population at risk for developing disseminated disease.
*Efforts to diagnose and screen individuals who harbor S.stercoralis should be made for patients who are candidates for immunosuppressive (eg, corticosteroid) therapy with relevant geographic history and peripheral eosinophilia.
==Screening modalities==
===Microscopic evaluation===
At least three ova and parasite examinations should be performed on separate days.
===Serology===
*An enzyme-linked immunosorbent assay (ELISA) for detecting serum IgG (Strongyloidesantibody) against a crude extract of the filariform larvae of S.stercoralisis available and should be used as a screening test for Strongyloides infection.
*However, because of cross-reactivity with other antigens, definitive diagnosis must also include identification of ova and parasites in stool specimens.


==References==
==References==

Revision as of 14:13, 9 August 2017

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis screening

CDC on Strongyloidiasis screening

Strongyloidiasis screening in the news

Blogs on Strongyloidiasis screening

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

According to the CDC, screening for strongyloidiasis is not recommended.[1]

Screening

  • Most fatal infections caused by S.stercoralis can be prevented by early detection and treatment of asymptomatic chronic infections.[2][3]
  • Screening is highly recommended to detect latent S.stercoralis infection before the start of chemotherapy or immunosuppression/steroid therapy in patients at risk.[4]
  • Repeated stool examination for ova and parasites or agar culture of stool may be the most appropriate approach.

Population at risk

  • In the U.S., residents of the Southeast may be at risk for strongyloidiasis by growing up in an endemic area.
  • Travelers and armed forces personnel may acquire infection during overseas trips to endemic areas (eg, southeast Asia, Central and South America, and Africa).
  • Refugees and immigrants from endemic areas
  • Immunocompromised patients, especially on corticosteroid therapy, are the most vulnerable population at risk for developing disseminated disease.
  • Efforts to diagnose and screen individuals who harbor S.stercoralis should be made for patients who are candidates for immunosuppressive (eg, corticosteroid) therapy with relevant geographic history and peripheral eosinophilia.

Screening modalities

Microscopic evaluation

At least three ova and parasite examinations should be performed on separate days.

Serology

  • An enzyme-linked immunosorbent assay (ELISA) for detecting serum IgG (Strongyloidesantibody) against a crude extract of the filariform larvae of S.stercoralisis available and should be used as a screening test for Strongyloides infection.
  • However, because of cross-reactivity with other antigens, definitive diagnosis must also include identification of ova and parasites in stool specimens.

References

  1. "CDC - Strongyloides".
  2. Mejia R, Nutman TB (2012). "Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis". Curr. Opin. Infect. Dis. 25 (4): 458–63. PMC 3430846. PMID 22691685.
  3. Al Maslamani MA, Al Soub HA, Al Khal AL, Al Bozom IA, Abu Khattab MJ, Chacko KC (2009). "Strongyloides stercoralis hyperinfection after corticosteroid therapy: a report of two cases". Ann Saudi Med. 29 (5): 397–401. PMC 2860402. PMID 19700900.
  4. "Department of Health | Prevention of opportunistic infections in immunosuppressed patients in the tropical Top End of the Northern Territory of Australia".